ArriVent registers Phase 1 trial of ARR-002 in ovarian and endometrial cancer

ArriVent BioPharma had one clinical trial update this week involving its antibody-drug conjugate ARR-002.

• ArriVent BioPharma is sponsoring a Phase 1 study (NCT07755436) of ARR-002 in adults with locally advanced or metastatic ovarian or endometrial cancer, listed as recruiting with a start date of July 23, 2026. The trial is an open-label, multicenter Phase 1a/1b dose-escalation and expansion study, with Phase 1a enrolling participants with platinum-resistant ovarian cancer to assess safety and tolerability, and Phase 1b enrolling separate cohorts of platinum-resistant ovarian cancer and endometrial cancer patients.¹ The study plans to enroll 180 participants¹ and is running at six sites in the United States, including Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Sarah Cannon Research Institute locations.¹